RE:RE:New Interview with Dr. McFarland - Fort Worth Report There is, " No standard of Care" that exists for these bladder cancer patients.
That's one of the reason why we've been granted FastTrack designation and that we will be granted Breakthrough and Accelerated Approval.
And if our CR% ends up being so high (70%+), that would mean that no other future biotech or big Pharma will ever invest in this indication to beat us, as the effort would not be worth the financial risk to invest in R&D. So we would end up dominating this field for decades, a bit like what BCG or chemo have been able to.
Many urologists mentioned that bladder cancer was a poorly funded indication. That's why BCG has been able to dominate for so many years, while unable to prevent recurrences in up to 70% of the cases. So no way one would suddenly want to invest during so many years to try to beat a 70% CR success.
So how much do you think our technology would be worth then?
How fierce one big Pharma would want such drug that would allow her to dominate this market for decades?
Name your price tag.